In this issue:
Tirzepatide vs. dulaglutide in type 2 diabetes: CV outcomes
Semaglutide and tirzepatide: comparable CV benefits in clinical practice
Orforglipron for addressing obesity in type 2 diabetes
Cortisol-directed therapy for hypercortisolism in poorly controlled type 2 diabetes
Tirzepatide for type 1 diabetes
Impact of semaglutide on automated insulin reductions in obese type 1 diabetes
Empagliflozin in HNF1A-MODY
Substituting ASBs with water in type 2 diabetes
GI safety of dulaglutide, semaglutide and tirzepatide in type 2 diabetes
AI as effective as humans for delivering diabetes prevention intervention
Please login below to download this issue (PDF)